Read More 1 minute read Analyst Ratings News Price Target Reiteration Needham Reiterates Buy on Freshworks, Maintains $25 Price Target By Benzinga Newsdesk February 8, 7:25 AM Needham analyst Scott Berg reiterates Freshworks (NASDAQ:FRSH) with a Buy and maintains $25 price target. FRSH
Read More 1 minute read Analyst Ratings News Price Target Reiteration HC Wainwright & Co. Reiterates Buy on Deciphera Pharmaceuticals, Maintains $25 Price Target By Benzinga Newsdesk February 8, 7:21 AM HC Wainwright & Co. analyst Andrew Fein reiterates Deciphera Pharmaceuticals (NASDAQ:DCPH) with a Buy and maintains $25 price target. DCPH
Read More 1 minute read Analyst Ratings News Price Target Reiteration HC Wainwright & Co. Reiterates Buy on Kiora Pharmaceuticals, Maintains $10 Price Target By Benzinga Newsdesk February 8, 7:20 AM HC Wainwright & Co. analyst Yi Chen reiterates Kiora Pharmaceuticals (NASDAQ:KPRX) with a Buy and maintains $10 price target. KPRX
Read More 1 minute read Analyst Ratings News Price Target Reiteration HC Wainwright & Co. Reiterates Buy on Indaptus Therapeutics, Maintains $15 Price Target By Benzinga Newsdesk February 8, 7:17 AM HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Indaptus Therapeutics (NASDAQ:INDP) with a Buy and maintains $15 price target. INDP
Read More 1 minute read Analyst Ratings News Price Target Reiteration HC Wainwright & Co. Reiterates Buy on Praxis Precision Medicine, Maintains $16 Price Target By Benzinga Newsdesk February 8, 7:14 AM HC Wainwright & Co. analyst Douglas Tsao reiterates Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and maintains $16 price target. PRAX
Read More 1 minute read Analyst Ratings News Price Target Reiteration Ladenburg Thalmann Reiterates Buy on Kiora Pharmaceuticals, Maintains $119 Price Target By Benzinga Newsdesk February 8, 6:54 AM Ladenburg Thalmann analyst Matthew Kaplan reiterates Kiora Pharmaceuticals (NASDAQ:KPRX) with a Buy and maintains $119 price target. KPRX
Read More 1 minute read Analyst Ratings News Price Target Reiteration Wedbush Reiterates Outperform on Microsoft, Maintains $280 Price Target By Benzinga Newsdesk February 8, 6:51 AM Wedbush analyst Daniel Ives reiterates Microsoft (NASDAQ:MSFT) with a Outperform and maintains $280 price target. MSFT
Read More 1 minute read Analyst Ratings News Price Target Reiteration SVB Leerink Reiterates Underperform on Incyte, Maintains $63 Price Target By Benzinga Newsdesk February 8, 6:50 AM SVB Leerink analyst Andrew Berens reiterates Incyte (NASDAQ:INCY) with a Underperform and maintains $63 price target. INCY
Read More 1 minute read Analyst Ratings News Price Target Reiteration Telsey Advisory Group Reiterates Outperform on VF, Maintains $36 Price Target By Benzinga Newsdesk February 8, 6:46 AM Telsey Advisory Group analyst Dana Telsey reiterates VF (NYSE:VFC) with a Outperform and maintains $36 price target. VFC
Read More 1 minute read Analyst Ratings News Price Target Reiteration SVB Leerink Reiterates Outperform on Deciphera Pharmaceuticals, Maintains $30 Price Target By Benzinga Newsdesk February 8, 6:10 AM SVB Leerink analyst Andrew Berens reiterates Deciphera Pharmaceuticals (NASDAQ:DCPH) with a Outperform and maintains $30 price target. DCPH